Physicians' Academy for Cardiovascular Education
ESC Heart Failure 2023 Ahmad Masri shares the results of the REDWOOD-HCM Cohort 4 trial, a phase 2 study with aficamten in non-obstructive HCM.
Treatment with SGLT2i lead to profound risk reductions in CKD. Meg Jardine discusses how we can improve implementation of SGLT2i for CKD in clinical practice.
In a pooled post hoc analysis of DAPA-HF and DELIVER the benefits of dapagliflozin were independent of gout status in patients with HF across the spectrum of LVEF.
Does intermittent fasting plus early time-restricted eating provide greater improvements in glycemic control, weight management or CV markers compared to calorie restriction or standard care in adults at risk of T2DM? The authors investigated this in a three-arm parallel group sequential RCT.
In an analysis of the EVAPORATE trial with prespecified endpoints, icosapent ethyl improved CT angiography–derived fractional flow reserve of coronary lesions after 9 and 18 months compared with placebo.
ESC Heart Failure 2023 Jozine ter Maaten shares the results of a subanalysis of STRONG-HF, which investigated the effects of high intensity HF care on renal function.
EAS Congress 2023 A Genome Wide Association Study in the 100,000 Genomes Project showed that a rare non-coding variant in the LPA gene is associated with mutation negative FH.
ESC Heart Failure 2023 Using data from IRONMAN, it was examined which marker of iron deficiency (TSAT, serum ferritin or anemia) best predicts response to intravenous iron in patients with HFrEF.
ESC Heart Failure 2023 Jasper Brugts summarizes the results of the MONITOR-HF trial, which investigated the efficacy of remote hemodynamic monitoring vs. standard care in patients with chronic HF.
Lale Tokgözoğlu provides an overview of studies that investigated the effects of omega-3 fatty acids with a focus on icosapent ethyl.
EAS Congress 2023 Stephen Nicholls is the recipient of the 2023 Anischkow Award. He summarizes the key messages of his lecture “Personalized Prevention of Atherosclerotic Cardiovascular Disease”.
ESC Heart Failure 2023 Robert Mentz presents the results of PARAGLIDE-HF, which reported greater reduction in NT-proBNP in the sacubitril/valsartan group vs. the valsartan group in HFmrEF/HFpEF after a worsening HF event.
